Halozyme Inc - Company & Market Research Reports

Halozyme was founded in 1998, the headquarters are located in San Diego, California. It is a biotechnology company that innovates cancer therapies that target the tumor microenvironment. PEGPH20, their main proprietary programme applies a unique approach to targeting solid tumors it may help make existing treatments more effective by allowing therapies to reach the tumor. Halozyme has teamed up with many partnering companies such as: Roche, Pfizer, Janssen, Baxalta, AbbVie and Lilly for the NHANZE™ drug delivery technology platform.


Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence - Product Thumbnail Image

Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 - Growth Driven by Increasing Uptake of Premium Priced Biologics and Rising Prevalence

  • Report
  • 171 Pages
From
Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence - Product Thumbnail Image

Breast Cancer Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rapid Uptake of Premium Priced Biologics and Rising Incidence

  • Report
  • 170 Pages
From
United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices - Product Thumbnail Image

United States Drug Delivery Devices Market Outlook to 2023 - Central Venous Catheters, Infusion Systems, Needle Free Injections and Metered Dose Inhaler Devices

  • Report
  • 980 Pages
From
Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update - Product Thumbnail Image

Competitor Analysis: Biosimilar & Biosuperior Therapeutic Antibodies - 2016 Update

  • Report
  • 462 Pages
From
Contact Dermatitis - Pipeline Insight, 2018 - Product Thumbnail Image

Contact Dermatitis - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Immune Checkpoint Inhibitors: Clinical Trial Tracker - Product Thumbnail Image

Immune Checkpoint Inhibitors: Clinical Trial Tracker

  • Clinical Trials
From
Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Gastric and Esophageal Cancer Drug Development Pipeline Review, 2017

  • Report
  • 244 Pages
From
Pancreatic Cancer - Pipeline Review, H2 2017 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H2 2017

  • Report
  • 2270 Pages
From
Pancreatic Cancer - Pipeline Review, H1 2017 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H1 2017

  • Report
  • 2092 Pages
From
Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 - Product Thumbnail Image

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

  • Report
  • 205 Pages
From
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H2 2016

  • Report
  • 250 Pages
From
Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2018 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016 - Product Thumbnail Image

Pancreatic Ductal Adenocarcinoma - Pipeline Review, H1 2016

  • Report
  • 221 Pages
From
Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022 - Product Thumbnail Image

Global Breast Cancer Therapeutics Market Analysis 2016 - Forecast to 2022

  • Report
  • 157 Pages
From
Metastatic Breast Cancer - Pipeline Review, H2 2016 - Product Thumbnail Image

Metastatic Breast Cancer - Pipeline Review, H2 2016

  • Report
  • 1096 Pages
From
Breast Cancer - Pipeline Review, H1 2016 - Product Thumbnail Image

Breast Cancer - Pipeline Review, H1 2016

  • Report
  • 3011 Pages
From
Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2024 - Product Thumbnail Image

Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2024

  • Report
  • 63 Pages
From
Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 325414 - Product Thumbnail Image

Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts: NAIC 325414

  • Report
  • 64 Pages
From
Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2022, NAIC 325414 - Product Thumbnail Image

Vaccines, Skin Replacement Products and Biologicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2022, NAIC 325414

  • Report
  • 65 Pages
From
Prefilled Syringes Market (4th Edition), 2017-2026 - Product Thumbnail Image

Prefilled Syringes Market (4th Edition), 2017-2026

  • Report
  • 525 Pages
From
Loading Indicator
adroll